A Multi-Center, Open-Label, Dose-Titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury.

Trial Profile

A Multi-Center, Open-Label, Dose-Titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2013

At a glance

  • Drugs Oxybutynin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Actavis Inc
  • Most Recent Events

    • 04 May 2010 Actual patient number (24) added as reported by ClinicalTrials.gov.
    • 06 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top